{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:47:14Z","timestamp":1761763634630},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[1998,7,1]],"date-time":"1998-07-01T00:00:00Z","timestamp":899251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":7861,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1998,7]]},"DOI":"10.1023\/a:1008286908930","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T13:47:34Z","timestamp":1040564854000},"page":"733-738","source":"Crossref","is-referenced-by-count":62,"title":["Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors"],"prefix":"10.1016","volume":"9","author":[{"given":"M.L.","family":"Rothenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Villalona-Calero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Aylesworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Kraynak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.I.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"H.A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.G.","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.D.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Forral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008286908930_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/07357909009017602","article-title":"Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine)","volume":"8","author":"Grindey","year":"1990","journal-title":"Cancer Invest"},{"key":"10.1023\/A:1008286908930_bb0015","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2,2-difluoro-2-deoxycytidine)","volume":"50","author":"Hertel","year":"1990","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008286908930_bb0020","first-page":"6110","article-title":"Action of 2',2'- difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang","year":"1991","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008286908930_bb0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","article-title":"Gemcitabine: A review of its phamacology and clinical potential in non-small-cell lung cancer and pancreatic cancer","volume":"54","author":"Noble","year":"1997","journal-title":"Drugs"},{"key":"10.1023\/A:1008286908930_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0305-7372(96)90014-6","article-title":"Clinical, toxicological, and pharmacological aspects of gemcitabine","volume":"22","author":"Guchelaar","year":"1996","journal-title":"Cancer Treat Rev"},{"issue":"4 Suppl 11","key":"10.1023\/A:1008286908930_bb0035","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo","volume":"22","author":"Peters","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008286908930_bb0040","first-page":"16","article-title":"Preclinical combination therapy with gemcitabine and mechanisms of resistance","volume":"23","author":"Peters","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008286908930_bb0045","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/bjc.1997.154","article-title":"In vitro cross resistance and collateral sensitivity in seven resistant small-cell-lung cancer cell lines: Preclinical identification of suitable drug partners to Taxotere, topotecan and gemcitabine","volume":"75","author":"Jensen","year":"1997","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"10.1023\/A:1008286908930_bb0050","first-page":"326a","article-title":"Gemcitabine is a pancytotoxic drug for various multiple myeloma cell lines, whereas Taxol cyctotoxicity is dependent on the expression of bcl-2","volume":"90","author":"Gazitt","year":"1997","journal-title":"Blood"},{"key":"10.1023\/A:1008286908930_bb0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2141.1996.d01-1912.x","article-title":"A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukemia: Preclinical cell culture studies","volume":"95","author":"Curtis","year":"1996","journal-title":"Br J Hematol"},{"key":"10.1023\/A:1008286908930_bb0060","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (Taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1008286908930_bb0065","first-page":"115","article-title":"A phase I trial of gemcitabine (LY 188011) administered intravenously every two weeks","volume":"10","author":"Brown","year":"1991","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008286908930_bb0070","first-page":"207","article-title":"Phase I study of gemcitabine (difluorodeoxycytidine; dFdC; LY 188011) administered in a two-weekly schedule","volume":"31","author":"Tanis","year":"1990","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"Suppl 1","key":"10.1023\/A:1008286908930_bb0075","first-page":"37","article-title":"Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer","volume":"23","author":"Tolcher","year":"1996","journal-title":"Semin Oncol"},{"issue":"Suppl 5","key":"10.1023\/A:1008286908930_bb0080","first-page":"72","article-title":"A phase I clinical trial of gemcitabine and paclitaxel in patents with recurrent epithelial ovarian cancer","volume":"7","author":"Poole","year":"1996","journal-title":"Ann Oncol"},{"issue":"Suppl 12","key":"10.1023\/A:1008286908930_bb0085","first-page":"S12-61","article-title":"Second-line treatment of advanced non-small-cell lung cancer with paclitaxel and gemcitabine: A preliminary report on an active regimen","volume":"24","author":"Georgoulias","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008286908930_bb0090","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008286908930_bb0095","first-page":"250","article-title":"Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma","volume":"15","author":"Moore","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008286908930_bb0100","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.1994.12.11.2264","article-title":"Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group","volume":"12","author":"Roth","year":"1994","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419559233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419559233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/9\/7\/733\/19482142\/9-7-733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T22:56:10Z","timestamp":1582239370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419559233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["S0923753419559233"],"URL":"https:\/\/doi.org\/10.1023\/a:1008286908930","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}